Evidence map›Paper›PMID 38205286›Full record

ArticleHeliyon2024

The engineering, drug release, and

Pegah Momeni, Maryam Nourisefat, Arman Farzaneh, Mohammad Shahrousvand, Mohammad Hossein Abdi

Abstract read
In one paragraph

Article in Heliyon, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Fabrication of Magnetic Poly(L-lactide) (PLLA)/FeMaterials (Basel, Switzerland) · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Pegah MomeniFaculty of Polymer Engineering, Sahand University of Technology, Tabriz, Iran.
Maryam NourisefatDepartment of polymer engineering and color technology, Amirkabir University of Technology, Tehran, Iran.
Arman FarzanehDepartment of polymer engineering and color technology, Amirkabir University of Technology, Tehran, Iran.
Mohammad ShahrousvandCaspian Faculty of Engineering, College of Engineering, University of Tehran, Rezvanshahr, P.O. Box: 43841-119, Guilan, Iran.
Mohammad Hossein AbdiSchool of Chemical and polymer Engineering, College of Engineering, University of Tehran, Tehran, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A system based on poly(l-lactic acid) (PLLA) and hydroxypropyl cellulose (HPC) was considered in this study to achieve electrospun mats with outstanding properties and applicability in biomedical engineering. A novel binary solvent system of chloroform/N,N-dimethylformamide (CF/DMF:70/30) was utilized to minimize the probable phase separation between the polymeric components. Moreover, Response Surface Methodology (RSM) was employed to model/optimize the process. Finally, to scrutinize the ability of the complex in terms of drug delivery, Calendula Officinalis (Marigold) extract was added to the solution of the optimal sample (Opt.PH), and then the set was electrospun (PHM). As a result, the presence of Marigold led to higher values of fiber diameter (262 ± 34 nm), pore size (483 ± 102 nm), and surface porosity (81.0 ± 7.3 %). As this drug could also prohibit the micro-scale phase separation, the PHM touched superior tensile strength and Young modulus of 11.3 ± 1.1 and 91.2 ± 4.2 MPa, respectively. Additionally, the cumulative release data demonstrated non-Fickian diffusion with the Korsmeyer-Peppas exponent and diffusion coefficient of n = 0.69 and D = 2.073 × 10

Indexed as

Biomedical applicationsCalendula Officinalis (marigold) extractElectrospun nanofibersHydroxypropyl cellulose (HPC)Poly (l-lactic acid) (PLLA)Response surface methodology (RSM)

Identifiers

PMID38205286
PMCPMC10777380

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.